Argipressin's Influence on Blood Loss During Hepatic Resection

PHASE4CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

March 27, 2022

Primary Completion Date

December 6, 2024

Study Completion Date

February 17, 2025

Conditions
Colon Cancer Liver MetastasisInflammatory ResponseVasopressin Causing Adverse Effects in Therapeutic Use
Interventions
DRUG

Argipressin

Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.

DRUG

Placebo

Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.

Trial Locations (1)

41345

Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
lead

Kristina Svennerholm

OTHER